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Abstract
Rationale: Valproic Acid is a commonly used psychiatric drug primarily used as a mood stabilizer. Mild hyperammonemia is a
Valproic Acid common adverse effect. This report presents an example of treated hyperammonemia on Valproic acid therapy
managed with L-carnitine administration in BD patients characterized by sudden vulnerability.
Patientconcerns:We report the case of a 29-year-old man suffering from bipolar disorder (BD) and substance use disorder who
exhibited sudden altered mental status upon admittance to the inpatient unit. The patient was started on Valproic acid with no
improvement.
Diagnoses: The patient had remarkably high ammonia levels (594mg/dL) without hepatic insufﬁciency, likely due to his valproate
treatment.
Interventions: The patient was administered lactulose, intravenous hydration, and i.v. levocarnitine supplementation 4.5g/day.
Outcomes:The administration leads to reduction of ammonia levels to 99mg/dL within 12 hours upon initiation of carnitine therapy
and progressive restore of his mental status within 24hours.
Lessons:Resolution of hyperammonemia caused by Valproic acid therapy may be enhanced with the administration of L-carnitine.
An interesting aspect of this case was how rapidly the patient responded to the carnitine therapy.
Abbreviations: AED= antiepiletic drug, AEs= adverse effects, AW= alcohol withdrawal, BD= bipolar disorder, BPD= borderline
personality disorder, CBZ = carbamazepine, ECG = electrocardiography, EEG = electroencephalogram, i.m = intramuscular, i.v =
intravenous, MR = mental retardation, o.s = oral administration, PB = phenytoin, PHT = phenobarbital, SUD = substance use
disorder, TBI = traumatic brain injury, VHE = valproate-induced hyperammonemic encephalopathy, VPA = valproic acid.
Keywords: bipolar disorder, carnitine, hepatic dysfunction, hyperammonemia, neurotoxicity, valproic acid1. Introduction
Valproic acid (VPA) is a broad-spectrum antiepileptic drug
(AED) that inhibits degradation, and promotes postsynaptic
transmission of gamma-aminobutyric acid (GABA).[1] VPA isEditor: Mirko Manchia.
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1widely used for the treatment of epilepsy, migraine, and a variety
of psychiatric symptoms, including bipolar disorder (BD),
borderline personality disorder (BPD), and alcohol withdrawal
(AW). VPA has been used effectively to reduce agitation and
aggression in both acute and postacute traumatic brain injury
(TBI) patients,[2,3] as well as a variety of other neuropsychiatric
syndromes, including dementia and mental retardation (MR).[4]
Overall, VPA is well tolerated with respect to cognitive
functioning, yet common, essentially dose-related, adverse effects
(AEs) include fatigue, gastrointestinal disturbances, weight gain,
tremor, hair loss, thrombocytopenia, teratogenicity. On the
contrary, pancreatitis, hepatotoxicity, and hyperammonemia are
infrequent AEs.[5]
Hyperammonemia can be deﬁned as a serum level of ammonia
higher than 50mmol/L. It can be due to genetic conditions in
newborns involving metabolism or liver disease, such as carnitine
deﬁciency, malignancies, or portosystemic shunts. Elevated levels
of ammonia can also be secondary to certain medications, such as
5-ﬂuorouracil, salicylate, asparaginase, acetazolamide, diuretics,
and VPA. Ammonia levels are increased in 12% to 52% of
asymptomatic patients treated with VPA.[6] A recent study
examined the frequency of hyperammonemia in a sample of older
adults taking VPA compared with those not taking such
medication, documenting 2-fold increased risk for hyperammo-
nemia following VPA intake.[7]
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We report the case of a 29-year-old male with lifetime diagnosis
BD, according to DMS-V criteria (APA, 2013), and substance use
disorder (SUD) who was forcedly hospitalized due to aggressive
behavior. His family history was negative for psychiatric illness,
while his personal history was also positive for childhood
epilepsy and characterized by several prior involuntary hospital-
izations occurred in similar contexts, and a poor compliance to
both psychiatric interviews and medications. He was receiving
haloperidol decanoate 150mg q 28 days: the latest injection had
been administered 4 days before hospitalization. His current SUD
involved both nicotine and substances of abuse; urine toxicology
screen performed at the Emergency Department (E.R.) docu-
mented the following records: opioids >2000ng/mL (negative
<300); cocaine >5000ng/mL (negative <300); benzodiazepines
898ng/mL (negative <200); buprenorphine 13ng/mL (negative
<5). Hemochrome, serum electrolytes, and liver functioning were
within normal ranges, as the electrocardiography (ECG) tracking
was.
Upon admission, he was alert and oriented to the person, place,
and time. He was irritable and aggressive. He was started on VPA
1000mg/day, lorazepam 7.5mg/day, ﬂurazepam 30mg/day per
o.s. (oral administration), and clotiapine 120mg/day i.m.
(intramuscular), which was later switched to oral formulation.
One week upon admission, plasma valproate level was 73mg/dL
(reference range 27–102).
Despite the pharmacological treatment, he was still disputa-
tious, irritable, suspicious, interpretative; he kept refusing
treatment and going against any rehabilitation program.
Thus, VPA was slowly increased up to 1800mg/day, clotiapine
and ﬂurazepam were stopped, while he started chlorpromazine
100mg/day and haloperidol 6mg/day.
Twenty days later, he showed no improvement in agitation,
rather he was still ﬂuctuating between aggressiveness and altered
consciousness through lethargy, altogether with an altered
walking mobility, characterized by an irregular gait pattern
with a widened base of support and a decreased step length. His
blood test revealed plasma valproate 124mg/dL; serum ammonia
was strikingly high—594mg/dL, while his liver function was
within normal range: aspartate aminotransferase (AST) 10U/L,
alanine aminotransferase (ALT) 8U/L, gamma-glutamyl trans-
peptidase (GGT) 12U/L, alkaline phosphatase (ALP) 59U/L,
prothrombin time International Normalized Ratio (PT INR)
1.13, Protothrombin Time Ratio (PR) 1.13, albumin 4.6g/dL.
Blood pressure was 110/70mm Hg and the heart rate was
88bpm. His temperature was 36.3°C and his respiratory rate was
20breaths/min.
The patient was not delivered to the intensive care unit, rather
he was treated on-site. VPA and antipsychotics were withdrawn,
and he was administered lactulose (20g orally 3 times a day),
intravenous (i.v.) hydration (1500mL/24h), and i.v. L-carnitine
supplementation 4.5g/day diluted in 0.9% sodium chloride
infusion solution. This latter treatment schedule was then
administered for 2 consecutive days.
Ammonia levels reduced to 99mg/dL about 12hours following
initiation of carnitine therapy; the patient’s mental status
gradually improved back to baseline over 24hours. At that
time, plasma VPA was back within therapeutic limits (65mg/dL).
Four days later, he underwent EEG (electroencephalogram),
which showed short sequences of slow-wave theta activity across
the temporal cortex, bilaterally, yet the baseline EEG tracing was
evaluated as normal. Abdominal ultrasonography showed a2slightly enlarged liver, yet homogeneous in structure and free
from focal lesions; gallbladder and bile ducts were also normal.
Twelve days after being diagnosed with hyperammoniemia,
he was alert, calm, cooperative, euthymic; impulsiveness had
recovered, motricity was normal. Hewas then discharged in good
clinical conditions (Fig. 1).
3. Discussion
VPA can cause hyperammonemia in the setting of both high and
therapeutic drug levels without evidence of hepatic dysfunction.
Prompt measurement of serum ammonia should be considered
when there is a decreased level of consciousness in patients
receiving VPA irrespective of the diagnosis and even after a long-
term exposure.
Hyperammonemia can be asymptomatic or may progress to
focal neurological deﬁcit, seizure, marked sedation, coma, due to
encephalopathy. Clinically signiﬁcant AEs occur in approxi-
mately 10% of the patients showing valproate-related hyper-
ammonemia, with ammonia levels about 2-fold increased beyond
normal ranges (35–65mmol/L). Yet, conclusive relationship
between the daily doses of VPA and the onset and severity of
VHE (valproate-induced hyperammonemic encephalopathy) has
not been established.[8] A direct relationship between the
development of VHE and serum VPA levels seems excluded,
even though data available in literature are not concordant.
VPA is known to be associated with decreased carnitine levels
and occasionally true deﬁciency, which is an unusual problem in
the healthy, well-nourished adult population. VPA depletes
carnitine storages through different mechanisms, usually in long-
term or high-dose treatment [9,10]: the effects of VPA on urea
metabolism occur primarily in the liver mitochondria, via the
inhibition of the enzyme required for the ﬁrst step in the urea
cycle, CPS1.[11] This may lead to a dose-independent increase in
the concentration of its substrate, ammonia, in the blood.[12]
Carnitine results also necessary in the mitochondria for the
transport and the subsequent oxidation of fatty acids.[13] VPA
inhibits carnitine transport, causing the increase in renal carnitine
excretion.[14] Indeed, a carnitine deﬁciency leads to the reduction
of fatty acids metabolism and the successive increase of protein
utilization. VPA also accelerates ammonia production by the
kidney [13]
L-carnitine is an aminoacid derivative and important nutrient
involved in fat metabolism. Up to 75% of L-carnitine is provided
by diet, particularly red meat and dairy products. It is also
biosynthesized endogenously from dietary amino acids (methio-
nin, lysine), especially in the liver and in the kidneys.[15] Carnitine
is responsible for 2 metabolic functions. It eases the fatty acyl-
group transport into mitochondria and it also preserves the ratio
of acyl-CoA to free CoA in the mitochondria. [16]
Carnitine supplementation has been suggested in the treatment
of a variety of health conditions such as cardiomyopathies,
diabetic neuropathy, tuberculosis, dementia, renal failure, and
anemia, and has been added to newborns’ foods and milk, even
though data are preliminary.[17]
As VPA-induced hyperammonemia and VHE could be
mediated at least in part by carnitine deﬁciency, it has been
hypothesized that L-carnitine supplementation may prevent,
correct, or attenuate these AEs.[16]
VPA-induced hyperammonemia is an AE that may be
prevented, corrected, or attenuated by L-carnitine supplementa-
tion because of VHE mediation, at least partly, by carnitine
deﬁciency. [16]
[18]
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Figure 1. Valproate-induced hyperammonemia development and treatment: timeline of a case report.
Cattaneo et al. Medicine (2017) 96:39 www.md-journal.comBohan et al analyzed the association of L-carnitine
treatment with hepatic survival in 92 patients with severe,
symptomatic, VPA-induced hepatotoxicity, reporting that
prompt intervention with i.v. rather than enteral L-carnitine
was associated with the greatest hepatic survival. Because of the
low (15%) bioavailability of enteral L-carnitine, the better
survival with i.v. treatment may be related to higher blood levels.
Some Authors [19,20] also suggest that carnitine might be
considered as a novel therapeutic option in the management of
depression and associated mood disorders, as well as attention-
deﬁcit hyperactivity disorder. Fernandes [21] reviewed the
emerging evidence on the role of carnitine in mood disorders,
yet results are not univocal: some studies examined depression
scores in further detail after 12 weeks of carnitine treatment,
whereas others found no statistically signiﬁcant negative
correlation between patients’ depression scores and total levels
of serum carnitine. Carnitine supplementation has also been
advocated in chronic VPA treatment, but data are limited [21].
In addition, patients who are treated with multiple anti-
convulsants—such as VPA combined with PHT (phenobarbital),
PB (phenytoin), or CBZ (carbamazepine)—are at a higher risk of
developing hyperammonemia [22]. Yamamoto et al [23] evaluated
a total of 2944 epileptic pediatric patients to identify risk factors
for hyperammonemia: the authors observed that the mean
ammonia level of the patients on VPA along with AEDs was
signiﬁcantly higher than that of those on VPA monotherapy,
especially when VPA was combined to PHT or PB, rather than3CBZ. The patient described herein was not suffering from
epilepsy, thus was not taking any other AED, which would have
increased his risk of developing hyperammonemia (and contrib-
uted to hindered interpretation of the results due to confounding
bias). His VPA serum levels were normal, but as we previously
observed, data in literature are not concordant with respect to a
direct relationship between the development of VHE and serum
VPA levels. Moreover, he had previously been treated with VPA,
without developing hyperammonemia, which reasonably allows
us to exclude a genetically inherited urea cycle disorder, even
though genetic testing was not performed.
In conclusion, resolution or prevention of hyperammonemia
may be enhanced with the administration of L-carnitine, yet
further investigation is required. An interesting aspect of this case
was how rapidly the patient responded to the carnitine therapy.References
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